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The therapeutic use of heat has in the past engendered 
great enthusiasm and occasionally great disappointment. 
However, it now holds promise as an effective and durable, 
minimally invasive treatment for symptomatic benign 
prostatic hyperplasia (BPH). The increasing population 
age and the greater attention paid by older men to the 
symptoms of BPH means that the demand for treatment is 
almost limitless. Current studies of the natural history of 
prostatic enlargement suggest that it has relatively few se­
rious connotations, and so great efforts have been made to 
lower the therapeutic burden for the patient. Transurethral 
resection of the prostate (TURP) in now being questioned 
as the “gold standard” treatment for every patient with 
symptomatic BPH because of the minor but significant 
rate of morbidity and failure in unselected patients. A host 
of interventional nonsurgical alternative treatments have 
emerged in the last 5 years [1-6]. The majority use ther­
mal energy applied to the prostatic adenoma by the rectal, 
urethral or even an extracorporeal route. Energy sources 
include laser, focused ultrasound, radiofrequency and mi­
crowave energy. Treatments may be divided into those 
which demand some form of general or regional anaesthe­
sia, often with a consequent need for an inpatient hospital 
stay, and those which can be easily accomplished without. 
For a treatment to truly not require anaesthesia, the energy 
must be precisely targeted, not require the use of rigid ure­
thral instrumentation, and the treatment session must be 
of short duration. Transurethral microwave thermotherapy 
(TUMT) complies with all these conditions.
Microwave energy was first applied to the prostate for 
the purpose of treating cancer, because of the selective 
sensitivity of malignant cells to heat [7]. The basic princi­
ple was subsequently used to treat symptomatic BPH. It 
became apparent that higher temperatures were required 
to irreversibly damage BPH cells [6]. The treatments were 
soon applied via the urethral route and developed from
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multi-session to single-session therapies [8J. TUMT is a 
method of delivering the energy to the lateral lobes, while 
simultaneously cooling the treatment and urethral sur­
faces. The authors, with their experience of over 1500 
treatments, review the current knowledge and discuss the 
future developments of TUMT.
Intraprostatic heating
Heating is the primary effect of microwave radiation in 
biological tissues and comparison of different modalities 
shows that the athermal biological effects of microwaves 
are negligible [9].Thus the clinical benefit of TUMT must 
be related to the achieved intraprostatic temperature, 
which results from a complex interaction between the bi­
ological response to microwaves and the pattern of energy 
provided during the treatment in any individual.
Microwave therapy relies on the predictable field of 
heating within homogeneous biological tissue. The effec­
tively heated volume is substantially reduced by the re­
markably efficient homeostatic mechanisms for heat dis­
sipation provided by the reactive increase in intraprostatic 
blood flow and the heat sink formed by the veins of San- 
torinis plexus. The combination of the predictable mi­
crowave field with the self-protective mechanism of the 
prostate means that properly designed microwave treat­
ments for BPH are remarkably safe. However, the vari­
able nature of each individual’s prostatic structure and 
potential blood flow also means that the induced heat is, 
to a certain extent, unpredictable.
Results of treatment
The results of treatment will be discussed under the fol­
lowing headings: (1) Prostasoft 2.0 results, (2) durability 
of response, (3) morbidity, (4) dose response, (5) selection 
criteria and (6) higher-power treatments.
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Table la. A review of TUMT data for in­
dividual symptom score changes compared 
to sham from baseline
Centre or country n Sham
Pre
Lyon [29] 22 15.9
Nijmegen [20] 50 12.1
London [14] 40 14.2
US [30] 120 14.9
France [31] 251 12.8
TUMT
Post Change Pre Post Change
(%) {%)
12.3 23 14. i 7.4 48
9.1 25 13.2 3.3 75
12.8 10 14.5 4.3 70
10.7 28 13.9 6,3 55
11.4 11 14.0 6,7 52
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ml/s ml/s Change mJ/s ml/s Change
(%) <%)
22 10.0 8.2 -18 10.5 13.1 25
50 9.7 11.3 17 9.6 14.0 46
40 8.6 9.2 7 8.5 13.0 53
120 7.4 9.5 28 7.3 11.5 58
251 10.7 9.7 -9 10.1 12.7 26
, Prostasoft 2,0 results
Transurethral microwave thermotherapy is performed on 
an outpatient basis in all patients. Treatment details have 
been described elsewhere [8, 10]. One of the concepts of 
TUMT is to preserve the urethral surface from the worst 
effects of heat, by using conductive cooling from water 
circulating within the applicator. Each treatment with 
TUMT is a computer-controlled process with negative 
feedback control of the power applicator and the circulat­
ing coolant temperature. Thresholds are set in the com­
puter control program, which defines the amount of energy 
supplied to the gland. The nature of the feedback control 
means that no one treatment is exactly the same as another.
Three versions of the operating software have been 
used in general clinical trials. The standard operating soft­
ware for the Prostatron is version 2.0, and worldwide, re­
markably similar clinical results have been reported from 
several centres [11-14]. Most studies use the Madsen- 
Iversen physician-guided symptom score (MSS) which 
ranges from 0 to 27. The mean entry level is usually 13 
and the expected outcome is a fall to around 4. Similar 
symptom scores can be found in elderly non-complaining 
men [15]. Clinically significant changes are demonstrated 
in all studies. Mean peak flow rate (PFR) changes have
*
ranged from 3 to 4 ml/s, representing a mean improve­
ment of about 35% over baseline. The changes in symp­
tom score and flow rate are noted from 6 weeks and per­
sist over a period of 2 years [16]. There are now five 
sham-controlled randomized studies using this software, 
all of which have demonstrated that the effect of TUMT is 
greater than can be accounted for by either the associated 
urethral instrumentation or by any placebo effect (Table 
1). In order to evaluate the clinical utility of TUMT, a ran­
domized study comparing it with TURP was performed 
by Petterson, Dahlstrand and their colleagues from Swe­
den. TUMT was seen to have a lesser effect on uroflow 
but had a very considerable impact on symptoms with 
lower morbidity [16]. TUMT is shown to have nearly the 
same symptom reduction as the “gold standard” treat­
ment. As expected, TUMT causes a significantly lesser 
change in PFR than seen with TURP,
Durability of response
The re-treatment rate after prostatectomy ranges up to 15% 
and depends on the interval of follow-up. It is unknown 
whether this re-treatment rate is related to the technique 
used, or to the dimensions of the cavity achieved by 
surgery. Clinical trials have shown a significant benefit 
from thermo therapy, although it is apparent that not all pa­
tients with BPH are completely relieved of their symptoms. 
In a long-term study at Charing Cross Hospital in London, 
100 patients were followed, and at 1 year 11% had required 
TURP for persistent symptoms or high residual urine [17]. 
De la Rosette et al. presented the results of a group of 130 
patients with the follow-up of 1 year [12]. In this group, 11 
patients were additionally treated with TURP. In a study by 
Dahlstrand et al. of 39 patients treated with TUMT, 4 pa­
tients were considered non-responders and, therefore, un­
derwent TURP [18]. Blute et al. presented the results of 
150 patients with a follow-up of 1 year, and 19 patients 
were regarded as non-responders [11], In contrast to these 
results, Van Cauwelaert et al. [19] and Tubaro et al. [13] 
show subjective and objective improvement, while the re­
treatment rate is acceptably low. However, the durability of 
response needs a longer follow-up.
Morbidity
The TUMT treatment is well tolerated by the patients. 
Perception of discomfort varies from a mild feeling of
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Table 2. The change in clinical parameters at 3 months relative to 
the final temperature achieved within the prostate with TUMT 












Low (43.K°C) 13 34 (7.4-9.9) 73 (14.7-4.0)
Medium (47.5° C) 16 43 (7.4-10.6) 76(15.0-3.6)
High (53.2° C) 10 79 (7.5-13.4) 90 (13.5-1.3)
Table 3. The proportion of subjects with 75% improvement (s u c ­
cess) in MSS and PFR in various TUMT studies
Study MSS PFR MSS and PFR
General 2.0 48% 24% 17%
General 2.5 42% 40% 22%
Compressive 44% 11% 1%
Constrictive 59% 55% 41%
Low temperature 54% 8% 8%
High temperature 90% 50% 40%
perineal warmth and a mild urge to urinate to occasional 
significant discomfort. Distraction and reassurance are 
usually enough, but momentary interruption of mi­
crowave emission may be useful in those with major 
discomfort. Most patients experience perineal discom­
fort and urinary urgency for several days after treatment, 
but not usually longer. Occasionally haematuria is no­
ticed. No tissue sloughing occurs, and urinary retention 
is expected in up to 25% of patients [6, 8, 10-14, 16, 
20]. In these cases, a catheter may be necessary for an 
average of 7 days. This procedure is not complicated by 
urinary tract infections. Prograde ejaculation is main­
tained and sexual function is unchanged. In the vast ma­
jority of patients the semen quality is also unchanged 
[211. No bladder neck contraction has been reported and 
no urethral strictures have been noticed thus far. From 
these data, we may conclude that urinary retention con­
stitutes the sole major complication and may easily be 
managed with an indwelling catheter for approximately
1 week.
Dose response
On a conceptual basis, the increase in thermal dose can be 
seen with the evolution of thermal treatment modalities 
for BPH patients. Transrectal hyperthermia has been 
shown to have virtually no histological effect; nor does it 
cause much increase in PFR [22]. Transurethral hyper­
thermia without cooling of the applicator has a greater ef­
fect on the tissue, and some histological changes have 
been seen, but the effect on flow rate remains small [23]. 
TUMT has a much greater histological effect and causes 
significant changes in PFR.
The elevation ot intraprostatic temperatures as mea­
sured by invasive thermometry during TUMT using ver­
sion 2.0 operating software has been shown to be broadly 
correlated with clinical outcome [24]. Patients whose 
baseline temperature was increased by an average of 8°C 
over the course of the 1-h treatment had significantly bet­
ter improvement in PFR and an improved clinical re­
sponse as shown by MSS (Table 2). Of particular note is 
that the number of patients who had a successful outcome, 
as defined by either an increase in PFR or decrease of 
MSS of greater than 75%, was significantly greater 
among those in whom a higher temperature was achieved 
(Table 3).
Selection criteria
Analysis of treatment outcome demonstrates considerable 
variability in individual response. Some patients do sur­
prisingly well, while other patients show almost no re­
sponse to treatment. In an attempt to provide selection cri­
teria, Devonec (personal communication) analysed the pa­
tient profile before treatment of a group of responders (n 
= 119) and non-responders (n = 111) to TUMT treatment. 
There was no difference in the two patient groups before 
treatment with regard to age, MSS, PFR, postvoid re­
sidual volume, or prostate volume. Devonec concluded 
that there are no clinical parameters either for prediction 
of clinical outcome or for selection of the ideal candi­
date.
Elasticity of the prostatic urethra has been previously 
discussed by Schäfer [25] in the description of specific 
types of obstruction. Plotting pressure and How values 
from a pressure flow (P-Q) tracing of patients on an X-Y 
diagram gives a hysteresis curve with an unique pattern. 
At one extreme, represented by a stenosis of the urethra, 
the hysteresis plot is characterised by a low value of the 
minimum opening pressure and a steep increase in detru­
sor pressure during the passage from minimum to maxi­
mum flow, due to reduced elasticity of the flow control­
ling zone (constrictive obstruction). At the other extreme 
(pure compressive obstruction), the hysteresis plot is 
characterised by a high value of the minimal opening 
pressure, because there is a difficulty in opening the flow 
controlling zone, and only a small increase in detrusor 
pressure during the transition from minimum to maximum 
flow, because the urethra can be easily expanded to reach 
its maximum cross-sectional area. The two extremes of 
these specific types of obstruction are seldom encountered 
in routine clinical practice, but any patient can be classi­
fied as having one or other form predominating.
If TUMT is able to modify elasticity of the prostatic 
urethra, patients suffering from reduced elasticity should 
be ideal candidates for this treatment modality [26, 27], 
Such a hypothesis has been tested in a retrospective analy­
sis of a large European multicentre study [28]. The analy­
sis showed that no single subjective or objective parame­
ter of BPH severity had a significant correlation with clin­
ical outcome after TUMT, although there was a trend for 
patients with lesser degrees of obstruction to do better. 
Constrictive obstruction was defined by a minimal ure­
thral opening pressure (pmuo) value <45 cm H20  and
vSlope value > 2.5; compressive obstruction was defined 
by a pmuo value > 45 cm H20  and/or a slope value < 2,5. 
The two groups were comparable at screening but differed 
significantly after treatment. Six months after treatment, 
the symptoms of BPH severity were significantly modi­
fied in both groups, with a trend towards a larger decrease 
in severity in constrictive patients than in compressive 
ones. No significant difference was found between the 
two groups with regard to symptoms or itroflow parame­
ters. However, the change in objective parameters after 
treatment differed significantly in the two groups. Patients 
with a predominantly constrictive pattern of obstruction 
had significantly greater improvement in both maximum 
and average (low rates, as well as decrease in residual 
urine, than those with compressive obstruction. From a 
urodynamic standpoint, the change in the slope of the pas­
sive urethral resistance relation of constrictive patients 
brought them back to a near-normal P-Q relation.
Clinical response to microwave thermotherapy is 
highly variable, and no consensus has been reached on 
how success and failure should be defined. Different 
guidelines have been proposed, and some of them have 
been recently endorsed by regulatory authorities. Evalua­
tion of clinical outcome by percentage improvement of 
MSS and  maximum How rate results in a success rate (> 
75% improvement) of 41.4% and 7.0% in constrictive and 
compressive obstruction patients, respectively. The failure 
rate (improvement < 25%) was (7.2% and 70.4%, respec­
tively,
In conclusion, it appears that the only possible way of 
identifying the patients who will respond best to TUMT 
using Prostasoft 2.0 is by formal measurement of the pres­
sure-flow relationship. Adoption of such parameters in 
prospective trials should improve the overall results, dura- 
bility of response and clinical utility of this treatment 
modality. Moreover, BPH is a complex disease, and urol­
ogists should maintain a central role in diagnosing the dis­
ease and in treating it when required. The urologist must 
be the expert on the disease, not just on its (surgical) treat­
ment.
Hig h e r-p o we r t re a tm e n ts
Further modifications to the operating software have been 
made in recent years in order to provide greater clinical 
efficacy. Higher temperatures may be the only way to 
achieve the removal of the obstruction. Currently, the ver­
sion of the operating software known as 2.5 is under eval­
uation. The programme is modified to provide more 
power at a maximum of 70 W  and a higher rectal thresh­
old leading to fewer treatment interruptions and an in­
crease in the energy delivered to the prostate. Overall, the 
maximum that can be delivered rises from 194.4 Id (aver­
age 110 Id) with version 2.0 to 219 Id (average 155 Id) 
with version 2.5. Not all patients will achieve this level 
because o f limitations imposed by the rectal and urethral 
alarms.
Simple clinical analysis of the outcome by means of 
PFR and M SS demonstrates a substantial advantage o f 2.5 
over the earlier version (Table 4). We believe that the 
great change in flow rate we have seen in patients receiv-
Tabk* 4, Changes in clinical parameters alter T U M T  employing 
ProsLasoft version 2.5 Uiatu from Nijmegen: HV residual urine)
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F ig ,la , b. Transrectal ultrasound of the prostate at 6 months post- 
T U M T  using Prostasoft version 2.5 software. Unequivocally, a 
cavity can be seen in both the transverse (a) and the sagital (b) 
plane
ing the 2.5 software treatment cannot be explained by 
anything other than a decrease of urodynamic obstruction, 
assuming the same contractility. However, there is a price 
to be paid in terms of morbidity. We feel that a catheter is 
needed in all patients for at least 1 week, and retention 
may be prolonged considerably beyond this. Cavities are 
frequently seen with ultrasound at 6 months (Fig. 0- As yet, 
selection criteria for the higher-power treatment have not 
been investigated. It is possible that it should only be used 
for patients who have severe obstruction as shown by 
pressure flow studies. We believe the relief of certain 




The findings of improved clinical results in certain patient 
groups in some studies suggest that the full clinical bene­
fit of TUMT has been under-reported. The objective must 
be to find the thermal dose, which will maintain a clini­
cally significant reduction in symptoms with objective ev­
idence of improved urinary flow and reduction in obstruc­
tion, while causing minimal post-treatment morbidity and 
still not necessitating anaesthesia. The maximum benefit 
of TUMT will be obtained only by selection of individual 
patients for specific therapeutic protocols.
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